company background image
AKUS

AkouosNasdaqGS:AKUS Stock Report

Market Cap

US$327.6m

7D

-5.1%

1Y

-51.8%

Updated

24 Oct, 2021

Data

Company Financials +
AKUS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AKUS Overview

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals.

Price History & Performance

Summary of all time highs, changes and price drops for Akouos
Historical stock prices
Current Share PriceUS$9.50
52 Week HighUS$9.39
52 Week LowUS$23.49
Beta0
1 Month Change-26.13%
3 Month Change-16.23%
1 Year Change-51.78%
3 Year Changen/a
5 Year Changen/a
Change since IPO-56.82%

Recent News & Updates

Jun 26
Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation

Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

May 07

Akouos names Kathy Reape as chief development officer

Akouos (AKUS) announces the appointment of Kathy Reape as the company's chief development officer. Reape brings over 20 years of experience in the pharmaceutical industry, including gene therapy translational and development expertise.Prior to joining Akouos, he was most recently Chief Medical Officer at Spark Therapeutics.

Shareholder Returns

AKUSUS BiotechsUS Market
7D-5.1%0.5%1.7%
1Y-51.8%16.1%30.3%

Return vs Industry: AKUS underperformed the US Biotechs industry which returned 16.1% over the past year.

Return vs Market: AKUS underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is AKUS's price volatile compared to industry and market?
AKUS volatility
AKUS Beta0
Industry Beta0.98
Market Beta1

Stable Share Price: AKUS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: AKUS's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201669Manny Simonshttps://www.akouos.com

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company’s precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene.

Akouos Fundamentals Summary

How do Akouos's earnings and revenue compare to its market cap?
AKUS fundamental statistics
Market CapUS$327.56m
Earnings (TTM)-US$64.46m
Revenue (TTM)n/a

0x

P/S Ratio

-5.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AKUS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$64.46m
Earnings-US$64.46m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.87
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did AKUS perform over the long term?

See historical performance and comparison

Valuation

Is Akouos undervalued compared to its fair value and its price relative to the market?

1.18x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AKUS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AKUS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AKUS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AKUS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AKUS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AKUS is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Akouos forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-7.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AKUS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AKUS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AKUS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AKUS is forecast to have no revenue next year.

High Growth Revenue: AKUS is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AKUS's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Akouos performed over the past 5 years?

-58.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: AKUS is currently unprofitable.

Growing Profit Margin: AKUS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if AKUS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare AKUS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AKUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: AKUS has a negative Return on Equity (-23.31%), as it is currently unprofitable.


Financial Health

How is Akouos's financial position?


Financial Position Analysis

Short Term Liabilities: AKUS's short term assets ($274.0M) exceed its short term liabilities ($12.1M).

Long Term Liabilities: AKUS's short term assets ($274.0M) exceed its long term liabilities ($28.0M).


Debt to Equity History and Analysis

Debt Level: AKUS is debt free.

Reducing Debt: AKUS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AKUS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AKUS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 56.7% each year


Dividend

What is Akouos's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AKUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AKUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AKUS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AKUS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AKUS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Manny Simons (38 yo)

5.58yrs

Tenure

US$7,175,702

Compensation

Dr. Emmanuel Simons, Ph D., M.B.A., also known as Manny, Co-founded Akouos in March 2016 and has been its President and Chief Executive Officer and Director since March 2016. Dr. Simons served as Principal...


CEO Compensation Analysis

Compensation vs Market: Manny's total compensation ($USD7.18M) is above average for companies of similar size in the US market ($USD1.68M).

Compensation vs Earnings: Manny's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AKUS's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: AKUS's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Akouos, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Akouos, Inc.
  • Ticker: AKUS
  • Exchange: NasdaqGS
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$327.562m
  • Shares outstanding: 34.48m
  • Website: https://www.akouos.com

Number of Employees


Location

  • Akouos, Inc.
  • 645 Summer Street
  • Suite 200
  • Boston
  • Massachusetts
  • 2210
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/24 22:03
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.